[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100148597":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":39,"collaborators":7,"id":42,"slug":7,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":7,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":43,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":7,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Vanderbilt-Ingram Cancer Center","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Tissue and blood collection","Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.",[13],{"name":14,"affiliation":5,"role":15},"Douglas Johnson, M.D.","PRINCIPAL_INVESTIGATOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":7},"Vanderbilt-Ingram Service for Timely Access","CONTACT","800-811-8480",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Vanderbitl-Ingram Cancer Center","RECRUITING","Nashville","Tennessee","United States","US",{"type":30,"coordinates":31},"Point",[32,33],-86.78444,36.16589,{"lat":33,"lon":32},[36,37],{"name":18,"role":19,"phone":20,"phoneExt":7,"email":7},{"name":38,"role":15,"phone":7,"phoneExt":7,"email":7},"Douglas Johnson, MD",{"type":15,"investigatorFullName":40,"investigatorTitle":41,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Douglas Johnson","Associate Professor of Medicine","100148597",false,"NCT01205815","Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment","Inclusion criteria\n\n* Pathologically-proven diagnosis of melanoma.\n* Patient must have a test or procedure that has the potential to provide left-over tissue that can be banked for future research purposes OR the patient has already had a diagnostic or therapeutic procedure but who has not yet been approached to participate is also eligible.\n\nExclusion criteria\n\n* Any patient with significant contraindications to venipuncture (e.g., severe anemia) will be excluded from blood collection procedures. However, if the patient provides consent and a paraffin-embedded block or 10-15 unstained slides of their tissue diagnosis, they will not be excluded from this protocol.\n* Any patient unable or unwilling to provide consent.","ALL","18 Years",{"count":50,"type":51},3000,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to identify biological characteristics occurring in the initiation and progression of melanoma.",[55],"Melanoma","2025-09-15",{"date":58,"type":59},"2025-09-19","ACTUAL",{"date":61,"type":59},"2010-06-03",{"date":63,"type":51},"2027-06",{"name":5,"class":6},1]